0 items
Your cart is empty.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
$51.00
This product is available by prescription only
This product does not require a prescription
Out Of Stock
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
The product is delivered in powdered (lyophilized) form and must be properly reconstituted prior to research use.
BPC-157 is a synthetic pentadecapeptide derived from the amino acid sequence of a gastric body protection compound, studied for its capacity to activate nitric oxide synthase pathway dynamics in endothelial and gastrointestinal tissue preclinical experimental models. eNOS pathway activation initiates downstream nitric oxide-mediated vasodilatory signaling cascade marker expression, cytoprotective pathway dynamics, and vascular endothelial regulatory marker activity. This nitric oxide pathway activation profile enables researchers to investigate BPC-157-mediated cytoprotective signaling mechanisms, downstream endothelial marker response characterization, and nitric oxide-dependent pathway interaction dynamics across multiple tissue-type preclinical experimental systems.
BPC-157 modulates VEGF receptor signaling pathway dynamics in preclinical endothelial and connective tissue experimental models, influencing downstream angiogenic cascade marker expression including VEGF-A upregulation, endothelial cell migration signaling pathway activity, and tubulogenesis regulatory marker dynamics. This angiogenic signaling profile enables research teams to investigate BPC-157-mediated vascular pathway marker characterization, dose-dependent VEGF cascade activation kinetics, and downstream endothelial reorganization pathway endpoint dynamics across gastrointestinal mucosal, tendon, and vascular tissue preclinical experimental systems.
Novera supplies BPC-157 5mg sourced from USA GMP-certified manufacturing facilities, independently verified to approximately 99% purity by third-party COA documentation. Each vial confirms pentadecapeptide sequence identity, purity grade, and batch-specific quality control data — providing research laboratories with consistent, pharmaceutical-grade gastric pentadecapeptide material for foundational and advanced cytoprotective signaling pathway research.
BPC-157 5mg is suited for research teams and cytoprotective signaling laboratories investigating nitric oxide synthase pathway activation dynamics, VEGF receptor-mediated angiogenic cascade marker characterization, and growth factor receptor interaction kinetics across gastrointestinal mucosal, musculoskeletal, and vascular tissue preclinical experimental models. Scientists examining eNOS pathway marker activity, downstream VEGF-A signaling cascade dynamics, and FAK/paxillin cytoskeletal reorganization pathway endpoint expression will find BPC-157 relevant to mechanistic cytoprotective and angiogenic signaling pharmacology study designs.
Research programs requiring a structurally defined gastric pentadecapeptide reference compound for foundational and pilot-phase preclinical studies benefit from the 5mg vial format, which supports precision working concentration calibration, dose-response threshold characterization, and multi-cycle experimental designs across early-stage protocol phases. Laboratories initiating baseline cytoprotective signaling pathway characterization prior to advancing to higher-concentration extended protocols will find the 5mg format particularly well-suited to systematic research progression study designs. Novera supplies BPC-157 5mg sourced from USA GMP-certified manufacturing facilities, with each vial COA-verified for purity and sequence identity to approximately 99%.
BPC-157 supports in vitro and preclinical investigation of gastrointestinal mucosal cytoprotective signaling dynamics, epithelial barrier integrity regulatory pathway marker expression, and gastric mucosal repair cascade characterization across intestinal epithelial cell and gastric mucosal preclinical experimental models. Researchers characterizing BPC-157-mediated eNOS pathway activation kinetics, downstream nitric oxide-dependent mucosal protective signaling marker activity, and gastrointestinal epithelial regenerative pathway endpoint dynamics use BPC-157 as a primary reference compound for mechanistic gastric cytoprotective pharmacology study designs.
Laboratories studying BPC-157-mediated angiogenic signaling use this compound to quantify VEGF-A upregulation dynamics, endothelial cell migration pathway marker activity, and downstream tubulogenesis regulatory cascade characterization in vascular endothelial preclinical experimental models. Multi-arm protocols examining dose-dependent angiogenic pathway marker response patterns across the 5mg concentration range support systematic dose-response threshold characterization and baseline angiogenic signaling pathway endpoint establishment prior to advancing to higher-concentration extended protocol phases.
BPC-157 enables preclinical investigation of tendon and ligament fibroblast signaling pathway dynamics, FAK/paxillin cytoskeletal reorganization marker expression, and growth factor receptor interaction kinetics in musculoskeletal tissue preclinical experimental models. Research examining BPC-157-mediated collagen synthesis regulatory pathway marker activity, satellite cell signaling cascade dynamics, and connective tissue fibroblast proliferation endpoint characterization uses this compound as a mechanistically defined cytoprotective reference tool for musculoskeletal signaling pathway study designs.
The 5mg vial format is particularly suited to foundational pilot-phase preclinical study designs requiring precise working concentration calibration, dose-response threshold characterization, and baseline cytoprotective signaling pathway endpoint establishment across gastrointestinal, vascular, and musculoskeletal experimental model systems. Multi-cycle experimental designs employing the 5mg format enable systematic baseline data collection and reproducibility validation across repeated experimental arms prior to protocol advancement, supporting structured research progression from foundational to extended higher-concentration study phases.
Reconstitute lyophilized BPC-157 5mg with sterile bacteriostatic water using standard sterile laboratory technique. Reconstitution volume should be determined based on the target experimental working concentration specified by the study design. Given the 5mg vial format’s particular suitability for precision dose-response and foundational baseline studies, accurate reconstitution volume calibration is critical to experimental concentration precision; document each reconstitution step in accordance with institutional research record-keeping standards. Use calibrated laboratory equipment throughout all preparation steps.
Store lyophilized pentadecapeptide at 2–8°C, protected from light and moisture, prior to reconstitution. Following reconstitution, maintain refrigeration at 2–8°C; reconstituted peptide remains stable for approximately 2–4 weeks under appropriate storage conditions. Cold-chain shipping is not required, but immediate refrigeration upon receipt is recommended to preserve pentadecapeptide sequence integrity throughout the protocol period. Each vial supplied by Novera includes COA documentation and handling guidance.
Foundational and pilot-phase preclinical cytoprotective signaling pathway studies using BPC-157 5mg typically span 2–6 week observation periods for baseline pathway marker characterization and dose-response threshold establishment. Extended multi-phase protocols may progress to longer observation periods following foundational baseline validation. Monitor nitric oxide pathway activity markers, VEGF-mediated angiogenic cascade dynamics, growth factor receptor interaction endpoint expression, and relevant tissue-specific cytoprotective signaling markers at defined experimental intervals throughout the observation period, in accordance with institutional laboratory standards.
Novera Research delivers high-quality research peptides developed under strict manufacturing and quality-control standards. Each product is carefully synthesized, tested, and handled to ensure consistency, reliability, and transparency for advanced research applications.
High-purity, research-grade peptide synthesis
Analytical testing to verify quality and composition
Consistent batch-to-batch performance
Batch identification on every vial for traceability
Stored and shipped under controlled conditions
Research-grade synthetic nonapeptide supplied in 5mg format for controlled in vitro laboratory investigation.
Research-grade cathelicidin-derived peptide formulated for experimental immune-related research in controlled laboratory environments.
Research-grade dual-peptide blend combining short-acting synthetic peptides for flexible laboratory research protocols.
A synthetic 44-amino acid analog of growth hormone-releasing hormone studied for pituitary receptor binding kinetics, GHRH pathway signaling dynamics, and downstream somatotropic axis marker activity in controlled preclinical models.
